Multifunctional Magnetic Resonance (MR) for Radiotherapy Planning in Prostate Cancer

Launched by ROYAL MARSDEN NHS FOUNDATION TRUST · Nov 2, 2009

Keywords

ClinConnect Summary

No description provided

Gender

MALE

Eligibility criteria

• Inclusion Criteria:
• • Hormone therapy naive patients planned to be treated by radical radiotherapy after 3-6 months of androgen suppression
• • Patients with low-high risk histologically confirmed localised disease are eligible, with WHO performance status 0-1.
• Exclusion Criteria:
• • Patients unsuitable for functional MRI of the prostate or gold seed fiducial marker insertion (e.g. patients unable to tolerate endorectal MRI examination).
• • No prior pelvic radiotherapy or radical prostatectomy, previous androgen therapy, patients unsuitable for radical radiotherapy, life expectancy \<10 years, previous active malignancy within last 5 years, co-morbid conditions likely to impact on the advisability of radical radiotherapy, full anticoagulation, other exclusions to MRI (e.g. hip prosthesis or fixation, claustrophobia, ferromagnetic implants).